Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Slight dent for Amylin seeking US approval of metreleptin for lipodystrophy

This article was originally published in Scrip

Executive Summary

Amylin Pharmaceuticals has revealed in a regulatory filing that the US FDA is seeking some updated data that relate to its rolling biologics license application (BLA) for metreleptin, an analogue of the human hormone leptin, which is under investigation to treat lipodystrophy, a rare metabolic disorder. Amylin said the regulator seeks updated data from the submitted clinical studies that remain ongoing.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017787

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel